KAMEL KAMEL: Open Payments
NPI 1811938541 · IRVINE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$301 in 5 payments from 3 companies in 2025. Trend: 2023 $619 · 2024 $214 · 2025 $301
Food & beverage: $301
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 2 | $137 |
| Neurocrine BioSciences, Inc. | 1 | $125 |
| E.R. Squibb & Sons, L.L.C. | 2 | $39 |
Products named: ABILIFY ASIMTUFII, INGREZZA, COBENFY, REXULTI.
Industry payments across CA — which companies pay providers there.
